The U.S. Food and Drug Administration (FDA) has approved a second indication for SKYRIZI® (risankizumab-rzaa) to treat adults with active psoriatic arthritis.
Psoriatic arthritis, a systemic inflammatory disease that affects the skin and joints, impacts approximately 30 percent of patients with psoriasis. This new approval makes SKYRIZI the only IL-23 inhibitor approved for adults with moderate to severe plaque psoriasis and active psoriatic arthritis that can be administered with a single injection four times a year (after two starter doses at weeks 0 and 4).
Tags: abbvie, skyrizi, risankizumab-rzaa, psoriatic arthritis